This phase I dose-escalation study investigated the safety and tolerability of evexomostat (SDX-7320), an optimized METAP2 inhibitor, in 32 patients with heavily pretreated, late-stage cancer with a variety of solid tumors and metabolic states. Here, METAP2 is linked to cancer.